[SSRI - treatment and bleeding. What risks do we take?].
Treatment with selective serotonin reuptake inhibitors (SSRI) increases the risk of gastrointestinal bleeding. The combination with non-steroidal anti-inflammatory drugs (NSAIDs) further augments this hazard. Particular precaution is also necessary in patients on platelet aggregation inhibitors, with a known bleeding disorder or preceding gastrointestinal lesions. The incidence of bleeding events apart from the gastrointestinal tract, e.g. intracerebral hemorrhages, is not cumulated under SSRI treatment. This also applies for the combination of SSRI and coumarin or aspirin. Prescribing doctors have to be aware of the bleeding risks of SSRI and should explain this to their patients. High-risk patients have to be followed up closely and an SSRI with a low potential for drug interaction should be used. The prescription of gastroprotective agents and a change of the antidepressant should be considered in particular cases. We provide a literature survey and recommendations for the clinical routine.
Strubel
T
T
Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie der TU München, Ismaningerstrasse 22, 81675, München, Deutschland. strubel@lrz.tu-muenchen.de
Birkhofer
A
A
Mössmer
G
G
Förstl
H
H
D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D017367:Selective Serotonin Reuptake Inhibitors
Blood Coagul Fibrinolysis. 1997 Nov;8(8):517-23
9491270
Eur J Clin Pharmacol. 2001 May;57(2):167-76
11417450
J Intern Med. 2007 Mar;261(3):205-13
17305643
Arch Intern Med. 2008 Jan 28;168(2):180-5
18227365
J Clin Psychopharmacol. 2005 Dec;25(6):561-4
16282838
Clin Pharmacol Ther. 2000 Oct;68(4):435-42
11061584
Dialogues Clin Neurosci. 2007;9(1):47-59
17506225
J Clin Psychopharmacol. 2008 Apr;28(2):230-4
18344737
Acta Psychiatr Scand. 2000 Oct;102(4):250-5
11089724
Pharmacotherapy. 2006 Sep;26(9):1307-13
16945053
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):304-10
16611206
Transl Res. 2008 Mar;151(3):168-72
18279816
Arch Intern Med. 2003 Jan 13;163(1):59-64
12523917
Drug Saf. 2004;27(14):1157-65
15554748
Arch Intern Med. 2003 Oct 27;163(19):2354-8
14581256
Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58
9537821
Circulation. 2001 Oct 16;104(16):1894-8
11602490
Drug Saf. 2008;31(2):159-68
18217791
BMJ. 2000 May 20;320(7246):1405-6
10858059
Circulation. 2003 Aug 26;108(8):939-44
12912814
Expert Opin Drug Saf. 2005 Mar;4(2):337-44
15794724
J Clin Psychopharmacol. 1993 Feb;13(1):75-6
8486822
Aliment Pharmacol Ther. 2005 Aug 1;22(3):175-81
16091054
Stroke. 2002 Jun;33(6):1465-73
12052976
Aliment Pharmacol Ther. 2006 Apr 1;23(7):937-44
16573796
Am J Med. 2006 Sep;119(9):719-27
16945603
Fortschr Neurol Psychiatr. 1998 Jan;66(1):32-5
9530554
Am J Med. 2006 Feb;119(2):113-6
16443409
Br J Clin Pharmacol. 2008 Jul;66(1):76-81
18460039
Stroke. 2007 Nov;38(11):3049-51
17901378
Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40
17919277
Arch Intern Med. 2004 Nov 22;164(21):2367-70
15557417
BMJ. 2001 Sep 22;323(7314):655-8
11566827
Thromb Haemost. 2002 Nov;88(5):705-10
12428081
Br J Clin Pharmacol. 2000 Jul;50(1):43-7
10886117
Br J Clin Pharmacol. 2003 Jun;55(6):591-5
12814454
BMJ. 1999 Oct 23;319(7217):1106-9
10531103